Tier 2 — strong

Enhanced Bioavailability and Pharmacokinetics of a Natural Self-Emulsifying Reversible Hybrid-Hydrogel System of Quercetin: A Randomized Double-Blinded Comparative Crossover Study

Ashil Joseph, Prasanth Shanmughan, Abhilash Balakrishnan, Balu Maliakel, Krishnakumar I M
ACS omega 2022 7(50):46825-46832

Bibliography

PubMed
PMID 36570285
PubMed Central
PMC9774360
DOI
10.1021/acsomega.2c05929
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
Reported disclosure: The authors declare the following competing financial interest(s): Hybrid-FENUMAT and QuerciFEN are the registered trademarks of Akay Natural Ingredients, Cochin, India who own the patent for the technology.

Study snapshot

DesignRandomized double-blind crossover pharmacokinetic study
ModelHuman intervention research
Sample16 healthy volunteers
InterventionFenugreek-galactomannan hybrid-hydrogel quercetin versus unformulated quercetin
DurationSingle-dose comparisons
EndpointsExposure and pharmacokinetics

What the study showed, in plain terms

Published in 2022, this source examined forms, absorption and food sources. Design: Randomized double-blind crossover pharmacokinetic study. Sample/model: 16 healthy volunteers. The exposure or intervention was Fenugreek-galactomannan hybrid-hydrogel quercetin versus unformulated quercetin. Follow-up or treatment period: Single-dose comparisons.

The formulation increased exposure, with different increases for unconjugated quercetin and total measured quercetin metabolites.

Product-specific pharmacokinetics. Total-metabolite and free-quercetin ratios are different, and neither proves greater clinical benefit.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Forms: Dihydrate, Phytosome, Liposomal and Glycosides. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • The formulation increased exposure, with different increases for unconjugated quercetin and total measured quercetin metabolites.
  • The recorded outcome domains were Exposure and pharmacokinetics.
  • The result applies to the tested exposure: Fenugreek-galactomannan hybrid-hydrogel quercetin versus unformulated quercetin; Single-dose comparisons.

What this study can and cannot tell us

  • Product-specific pharmacokinetics. Total-metabolite and free-quercetin ratios are different, and neither proves greater clinical benefit.
  • A change in blood exposure or a metabolic marker is not a demonstrated improvement in symptoms, disease events or lifespan. The tested formulation and co-administered medicines matter.
  • Source basis: Source check: accessible full text and indexed metadata. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Improving quercetin bioavailability: A systematic review and meta-analysis of human intervention studies
Lu Liu et al. · Food chemistry · 2025
Tier 2
Microbiological and Pharmacokinetic Aspects of a Water-Soluble Quercetin 3-O-rutinoside, EubioQuercetin: A Direct Comparison With Quercetin in In Vitro and Human Clinical Studies
Naoto Yamaguchi et al. · Journal of food science · 2025
Tier 2
Comparative Pharmacokinetics and Safety of a Micellar Chrysin-Quercetin-Rutin Formulation: A Randomized Crossover Trial
Afoke Ibi et al. · Antioxidants (Basel, Switzerland) · 2025
Tier 2
Enzymatically modified isoquercitrin improves endothelial function in volunteers at risk of cardiovascular disease
Nicola P Bondonno et al. · The British journal of nutrition · 2020

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology